ライフサイエンスコーパス: DBS

1 DBS and DE associated with CAF presented satisfactory cl

2 DBS and urine samples are being collected from the older

3 DBS are collected at birth for the child.

4 DBS collection can enhance the reliability of assessment

5 DBS is a standard of care in Parkinson disease, essentia

6 DBS sample CRP measurements were made by enzyme-linked i

7 related with genotyping success (P < 0.001); DBS samples with corresponding plasma viral load >250 co

8 Over a 1-year period, we collected 125 DBS cards, of which 45 had already been diagnosed by MS-

9 We selected 150 DBS specimens from ongoing studies of antiretroviral the

10 of 3 healthy individuals, 4 PD cases, and 3 DBS-treated patients.

11 re documented in 116 patients with PD from 3 DBS centers (Berlin, Queensland, and Cologne).

12 ous methods, DeepMS could discover 37 SBS, 5 DBS, and 9 Indel new signatures, many of which represent

13 , PSC at low-volume sites; (4) PSC only; (5) DBS only.

14 A DBS is eluted with 500 muL of elution solvent in a sampl

15 ation target dependent brain circuitry for a DBS outcome.

16 y aimed to develop, evaluate, and validate a DBS-based method to assess MeHg and inorganic mercury (I

17 dels may inform clinical improvements across DBS targets, surgeons and centers.

18 Third, activating DBS reduced tremor (p < 0.01) but had no effect on dysme

19 e study, study participants receiving active DBS underwent 1.5- or 3-T MRI (T1-weighted imaging and g

20 n a large cohort of participants with active DBS systems and characterize the hardware-related artifa

21 lly effective target for beta-based adaptive DBS.

22 lly effective target for beta-based adaptive DBS.SIGNIFICANCE STATEMENT It is known that subthalamic

23 (DBS) has now been translated into adaptive DBS paradigms, a limited number of studies have characte

24 intenance phase, approximately 2 years after DBS surgery, and changes in depression scores and occurr

25 The alternating DBS (altDBS) could entrain patients' stepping rhythm, su

26 s reduced ABL utility by 72.6% (+/-4.0%) and DBS utility by 71.7% (+/-4.3%).

27 of impulsivity and especially medication and DBS-associated impulsivity in PD.

28 This new ARSA DBS assay can serve as a second-tier test following the

29 The mean (SD) age at DBS implantation was 41.0 (11.4) years, and the follow-u

30 Baseline DBS ELISA assay CRP measures yielded a mean positive bia

31 study indicates reasonable agreement between DBS and the reference method, especially at low to mid-r

32 n basic science and clinical practice beyond DBS, offering a wealth of information related to normal

33 Bilateral DBS electrodes may be implanted within a single operatio

34 ts from a previous trial, received bilateral DBS of the ventral anterior limb of the internal capsule

35 neurons in PD brains vs. DBS-treated brains, DBS treatment seemed to have inhibited or reversed the r

36 ease in pyramidal neuron activity induced by DBS or by a stimulation of cortical somatostatin interne

37 indicate that measures of MeHg in capillary DBS reflect concentrations in the gold standard (i.e., v

38 s demonstrated by application to dog and cat DBS samples.

39 Intergroup comparison (DBS x DE) demonstrated no significant differences consid

40 Conventional DBS-fMRI, however, lacks the sensitivity needed for deco

41 nstructed binary tree of significant degree, DBS informs whether the results of segmentation are over

42 We tested three different DBS-DNA extraction techniques assessing the DNA concentr

43 compared with 2 and 4 week samples from DOT-DBS (NCT02022657).

44 ) showed 40% Y-BOCS score improvement during DBS, and a prospective international multi-center study

45 Each DBS-DNA extraction method was capable of accuracy in det

46 Stimulation in each DBS target had similar therapeutic effects, however, ant

47 An efficient and effective DBS analytical method could facilitate the concentration

48 allidus internus (GPi), an equally effective DBS target.

49 follow the high rates required for effective DBS, and thus the contribution of activation of STN neur

50 a probabilistic stimulation map of effective DBS.

51 ost of uptake/correct VL result using either DBSs or PSCs to increase VL access on equipment availabl

52 in forelimb stepping similarly to electrical DBS, while optogenetic STN DBS with ChR2 did not produce

53 As with electrical DBS, optogenetic STN DBS exhibited a strong dependence o

54 known DBS samples by punching out the entire DBS or by subpunching a small section of a large DBS wit

55 ing thalamic deep brain stimulation (DBS; ET(DBS) ) to 19 healthy controls (HC).

56 First, ET(DBS) and ET exhibited greater dysmetria than HC and dysm

57 ates significant benefits in HRQoL following DBS in patients with inherited or idiopathic isolated dy

58 d mental domains of SF-36 improved following DBS with a significantly larger effect size for the phys

59 (DBS) analysis is assumed to be constant for DBS punches with a fixed area.

60 E-C(4)D determination of K(+) and Na(+) (for DBS volume calculation) and amino acids (target analytes

61 This highlights the importance of NMS for DBS outcomes assessments.

62 In our experience, DNA extracted from DBS analyzed by the MS-HRM methodology provides an accur

63 Total nucleic acid was extracted from DBS, reverse transcribed, PCR amplified, and analyzed by

64 te notwithstanding, it is likely that future DBS for memory will employ closed-loop, nuanced approach

65 GPi DBS outcomes vary across monogenic dystonias.

66 hort Form Health Survey-36 (SF-36) after GPi DBS in patients with inherited or idiopathic isolated dy

67 rlying the therapeutic effect of STN and GPi DBS.

68 We sought to compare GPi DBS outcomes among the most common monogenic dystonias.

69 ntidromic activation not observed during GPi DBS, raise questions about its role as the primary mecha

70 ion of the globus pallidus pars interna (GPi DBS).

71 fect of age, sex and disease duration on GPi DBS outcomes.

72 allidus internus deep brain stimulation (GPi DBS) on health-related quality of life (HRQoL) in patien

73 onfirmed monogenic dystonia treated with GPi DBS documenting pre-surgical and post-surgical assessmen

74 (STN) DBS and globus pallidus internus (GPi) DBS.

75 of brain disorders are poised to reshape how DBS is viewed and delivered to patients.

76 However, DBS group presented inferior pain/discomfort compared wi

77 However, DBS presented inferior morbidity, an important fact for

78 4me3 and H3K27me3 in its resistant NIL; (ii) DBSs for H3K27me3 mark were more abundant (> 80%) in int

79 However, risks associated with imaging DBS devices have led to stringent regulations, limiting

80 C, the first FDA-approved, fully-implantable DBS device capable of nearly-simultaneous electrophysiol

81 here is a clear need for a fully-implantable DBS system capable of chronically recording patient-spec

82 d local field potentials (LFPs) at implanted DBS leads was validated in patients with neurological di

83 may potentially form the basis for improved DBS strategies for gait.

84 stigators are primarily focused on improving DBS device and MRI safety through the development of too

85 ity of using this approach, Nf-L analysis in DBS/DPS is compared to that in plasma obtained from the

86 TGW had comparable TFV-DP concentrations in DBS after 4 weeks of directly observed daily FTC/TDF PrE

87 lysis is likely to perturb Nf-L detection in DBS elute.

88 We evaluated TFV-DP in DBS following daily oral PrEP (emtricitabine 200mg/tenof

89 ood for plasma viral load (VL) and TFV-DP in DBS were collected (up to 3 visits within 48 weeks) in P

90 8% of RAM found in plasma were also found in DBS, and replicate DBS genotyping revealed that a single

91 parse BOLD patterns which are often found in DBS.

92 aplotypes with 5% within sample frequency in DBS with 100 parasites/uL).

93 n were higher for InHg (1.9 and 1.1 mug/L in DBS and whole blood, respectively) than MeHg (0.3 and 0.

94 espectively) than MeHg (0.3 and 0.2 mug/L in DBS and whole blood, respectively).

95 rt the detection of different Nf-L levels in DBS elute compared to reference plasma and DPS from the

96 ARSA activity was measured in DBS for the first time without an antibody.

97 However, Nf-L measurement in DBS elutes provides a very good discrimination of ALS fr

98 test following the sulfatide measurement in DBS for newborn screening of MLD.

99 uired to evaluate mercury (Hg) speciation in DBS and to validate the agreement between blood sources

100 Determining the next steps in DBS science will help to define the future role of this

101 Further studies into DBS-based Nf-L detection and its analytical optimization

102 Matched venepuncture and finger lancet DBS samples were collected from n = 100 RA patients with

103 or by subpunching a small section of a large DBS with variations of the true vs the determined volume

104 rizing these patterns is crucial for linking DBS-induced therapeutic and adverse effects.

105 The manual DBS handling is thus reduced to inserting the DBS punch

106 ume collected on the volumetric microfluidic DBS card were compared to volume-controlled pipetted DBS

107 Modern DBS systems, borrowed from the cardiac field, consist of

108 ing remains the most serious risk for modern DBS devices.

109 act this network modulation has on non-motor DBS effects is not well-characterized.

110 on mapping to a retrospective, multidisorder DBS dataset assembled over 15 years at our institution (

111 raction indicated underpinning nanofibrillar DBS networks, and differential scanning calorimetry show

112 alistic lead trajectories obtained from nine DBS patients.

113 Four non-DBS-related serious adverse events occurred, including o

114 and distinguish dysmetria from tremor in non-DBS ET.

115 ated this association in an independent, non-DBS PD cohort (N = 88).

116 and clinical efficacy of subthalamic nucleus DBS with a novel MICC device for the treatment of motor

117 ntrolled trial to assess subthalamic nucleus DBS, with a novel multiple independent contact current-c

118 a high potential for the direct analysis of DBS samples since DBS elution and HF-LPME are performed

119 as a potential basis for the development of DBS strategies to ameliorate gait impairments.SIGNIFICAN

120 ive overview of the technical development of DBS, from its origins to its future.

121 chanism underlying the therapeutic effect of DBS.

122 chanism underlying the therapeutic effect of DBS.

123 amined the tolerability and effectiveness of DBS in an open study of patients with refractory OCD.

124 isolated dystonia to evaluate the effects of DBS on physical and mental QoL.

125 of STN neurons to the therapeutic effects of DBS remains unclear.

126 Adverse effects of DBS were examined with a structured interview (n = 38).

127 portant factor in the therapeutic effects of DBS.SIGNIFICANCE STATEMENT Recently there has been great

128 Understanding the evolution of DBS technology helps put the currently available systems

129 The obtained conversion factors of DBS to plasma concentrations of dabigatran, apixaban, an

130 ion Rating Scale (MADRS) during 12 months of DBS (timeline analysis).

131 Twelve months of DBS resulted in a mean Y-BOCS score decrease of 13.5 poi

132 significantly during the first 12 months of DBS.

133 ill likely contribute to the optimization of DBS target selection and improved outcomes for patients.

134 ults confirm the effectiveness and safety of DBS of the vALIC for patients with treatment-refractory

135 ive was to assess the efficacy and safety of DBS targeted at the ventral anterior limb of the interna

136 veness and the optimal stimulation target of DBS for CCH remain unclear.

137 long-term effectiveness and tolerability of DBS and its impact on functioning and well-being.

138 to enhance the efficacy and tolerability of DBS.

139 Recent failed clinical trials of DBS in major depression, and modest treatment outcomes i

140 hree conditions: on-med/pre-DBS, off-med/off-DBS, and on-med/on-DBS.

141 rivaroxaban, and apixaban concentrations on DBS cards.

142 mate blood volume and NOAC concentrations on DBS cards.

143 -med/pre-DBS, off-med/off-DBS, and on-med/on-DBS.

144 High-rate optogenetic DBS generated both increases and decreases in firing rat

145 Paired DBS and plasma samples from patients undergoing NOAC the

146 In paired DBS-plasma genotypes, 83.8% of RAM found in plasma were

147 t, we used volume-controlled (40 muL) paired DBS-whole blood samples to develop an analytical method

148 carried out a validation study using paired DBS-whole blood samples from venous and capillary source

149 A PD DBS cohort (N = 37) completed a reward-based Go/No-Go ta

150 were compared to volume-controlled pipetted DBS samples from the same finger prick.

151 correct VL result was lowest in the plasma + DBS scenario at $30.90 compared to $31.62 in our plasma

152 Moreover, PPN DBS selectively improved learning from rewards but not f

153 al analyses indicated that the effect of PPN DBS on instrumental learning was best captured by an inc

154 le doped with dodecyl benzenesulfonate (PPy (DBS)) is placed over RTN in an ex-vivo en bloc brain and

155 the task under three conditions: on-med/pre-DBS, off-med/off-DBS, and on-med/on-DBS.

156 The authors quantified DBS hardware-related artifacts on images from GRE-EPI (f

157 sents an important milestone in quantitative DBS analysis since the detection technique is universal,

158 ith severe treatment-refractory OCD received DBS of the ventral part of the anterior limb of the inte

159 Sixteen patients suffering from TRD received DBS of the slMFB and were randomized to sham or real sti

160 plasma were also found in DBS, and replicate DBS genotyping revealed that a single test detected 86.7

161 ith SCTG harvested by: double blade scalpel (DBS) and de-epithelialized (DE) SCTG.

162 icipants enrolled in a clinical trial of SCC DBS for treatment-resistant depression.

163 and sustained antidepressant response to SCC DBS.

164 for the direct analysis of DBS samples since DBS elution and HF-LPME are performed simultaneously dur

165 (i) large scale differential binding sites (DBS) were available for only H3K4me3 in the susceptible

166 tatus quo); (2) plasma at high-volume sites, DBS at low-volume sites; (3) plasma at high-volume sites

167 1,3:2,4-Dibenzylidene-d-sorbitol (DBS), a simple, commercially relevant compound, was foun

168 Blood volume in dried blood spot (DBS) analysis is assumed to be constant for DBS punches

169 a part of data collection, dried blood spot (DBS) and urine samples are being collected three times d

170 100 targets and applied to dried blood spot (DBS) controls and field isolates from Mozambique.

171 ied species extracted from dried blood spot (DBS) samples with virtually no sample preparation.

172 ing (MS-HRM) approach from dried blood spot (DBS) samples, assessing the different DNA isolation tech

173 ical solutions, urine, and dried blood spot (DBS) samples.

174 Dried blood spot (DBS) specimens were tested for neutralizing antibodies t

175 een CRP values obtained by dried blood spot (DBS) versus conventional venepuncture sampling.

176 ood fractions obtained from dry blood spots (DBS) and dry plasma spots (DPS), two filter paper-based

177 rbon (BC), and collecting dried blood spots (DBS) and urinary samples for biomarker analysis.

178 concentration measured in dried blood spots (DBS) is used to monitor cumulative adherence to pre-expo

179 d methylmercury (MeHg) in dried blood spots (DBS) though more research is required to evaluate mercur

180 ctivity in leukocytes and dried blood spots (DBS) using deuterated natural sulfatide substrate.

181 Dried blood spots (DBS)-based drug resistance testing, widely studied for H

182 Dried blood spots (DBSs) could circumvent many logistical challenges at the

183 The importance of dried blood spots (DBSs) has increased in medical care.

184 Dried blood spots (DBSs) were collected to estimate seroprotection against

185 Excited dipole-bound states (DBSs) are uncovered for the three anions by photodetachm

186 Deep brain stimulation (DBS) can be an effective therapy for tics and comorbidit

187 Deep brain stimulation (DBS) depends on precise delivery of electrical current t

188 ations recorded from deep brain stimulation (DBS) electrodes within the VS are a pragmatic source of

189 peutic mechanisms of deep brain stimulation (DBS) for Parkinson's disease.

190 et to emerge whether deep brain stimulation (DBS) for treatment-refractory obsessive-compulsive disor

191 Deep brain stimulation (DBS) has been proposed for severe, chronic, treatment-re

192 Deep brain stimulation (DBS) has been shown to be an effective treatment for mov

193 patients undergoing deep brain stimulation (DBS) has now been translated into adaptive DBS paradigms

194 ulsive disorder with deep brain stimulation (DBS) have been proposed.

195 alamic nucleus (STN) deep brain stimulation (DBS) in Parkinson's disease (PD) remains unclear.

196 peutic impact of PPN deep-brain stimulation (DBS) in three patients with Parkinson disease.

197 rgic medications and deep brain stimulation (DBS) influence Pavlovian bias.

198 Deep brain stimulation (DBS) is a neurosurgical procedure that allows targeted c

199 Deep brain stimulation (DBS) is a treatment option for refractory chronic cluste

200 Deep brain stimulation (DBS) is an effective intervention for patients with seve

201 Deep brain stimulation (DBS) is an effective treatment option for patients with

202 Deep brain stimulation (DBS) is used to treat a wide array of neurologic conditi

203 Direct or indirect deep brain stimulation (DBS) of the entorhinal-hippocampal system, the brain's m

204 Deep brain stimulation (DBS) of the subthalamic nucleus (STN) and globus pallidu

205 Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective th

206 's can be treated by deep brain stimulation (DBS) of the subthalamic nucleus (STN).

207 Deep brain stimulation (DBS) of the subthalamic nucleus is a symptomatic treatme

208 Deep brain stimulation (DBS) of the subthalamic nucleus is an established therap

209 Deep brain stimulation (DBS) reduces depressive symptoms in approximately 40%-60

210 ndergone therapeutic deep brain stimulation (DBS), as in these individuals we can stimulate the STNs

211 Deep brain stimulation (DBS), targeting the subthalamic nucleus (STN) and globus

212 h bilateral thalamic deep brain stimulation (DBS).

213 effective target for deep brain stimulation (DBS).

214 patients undergoing deep brain stimulation (DBS).

215 successful sites of deep brain stimulation (DBS; essential tremor).

216 undergoing thalamic deep brain stimulation (DBS; ET(DBS) ) to 19 healthy controls (HC).

217 Over 4 h of continuous STN DBS, antidromic activation became less robust, whereas t

218 on of antidromic activation of M1 during STN DBS in disrupting synchronization in cortical neuronal p

219 ctivation of M1 was only observed during STN DBS.

220 diating the symptom-relieving effects of STN DBS using cell type-specific optogenetic stimulation wit

221 ctivation at least in the acute phase of STN DBS, the difference in observed antidromic activation be

222 Optogenetic STN DBS at 130 pulses per second (pps) reduced pathologic ci

223 High-rate optogenetic STN DBS can indeed ameliorate parkinsonian motor symptoms th

224 As with electrical DBS, optogenetic STN DBS exhibited a strong dependence on stimulation rate; h

225 oral and neuronal effects of optogenetic STN DBS in female rats following unilateral 6-hydroxydopamin

226 rly to electrical DBS, while optogenetic STN DBS with ChR2 did not produce behavioral effects.

227 in patients with PD who underwent staged STN DBS.

228 Although both animals undergoing STN DBS had similar beneficial effects, the proportion of an

229 an primates during subthalamic nucleus (STN) DBS and globus pallidus internus (GPi) DBS.

230 ate of neuropsychiatric impairment after STN-DBS and suggest that tractography could be used to predi

231 Depressive symptoms before and after STN-DBS surgery were documented in 116 patients with PD from

232 n of neuropsychiatric side-effects after STN-DBS.

233 between-group differences, all favouring STN-DBS, were found for NMSS, SCOPA-motor complications, LED

234 changes in depressive symptoms following STN-DBS, which have been reported to improve, worsen, or rem

235 Our results suggest that for the left STN-DBS lead, placement impacting fibers to left prefrontal

236 After 36 months, STN-DBS significantly improved NMSS, PDQ-8, SCOPA-motor exam

237 s IIb evidence for beneficial effects of STN-DBS on NMS at 36-month follow-up which also correlated w

238 g applied on the cohort of 151 patients (STN-DBS n=67, MED n=84) resulted in a well-balanced sub-coho

239 Subthalamic deep brain stimulation (STN-DBS) for Parkinson's disease treats motor symptoms and i

240 thalamic nucleus deep brain stimulation (STN-DBS) in Parkinson's disease (PD) not only stimulates foc

241 and clinical characteristics between the STN-DBS and MED groups.

242 d Yahr stage 2.6) were assessed prior to STN-DBS and 3 months postoperatively.

243 nd response inhibition networks prior to STN-DBS was not associated with postoperative impulsivity; r

244 inked to depressive symptom change under STN-DBS.

245 s (SBSs), 11 for doublet base substitutions (DBSs) and 16 for small insertions and deletions (Indels)

246 This supports DBS as a viable treatment option for patients with TRD.

247 we manipulated tremor amplitude by switching DBS ON and OFF to examine its effect on dysmetria.

248 t in essential tremor patients with thalamic DBS.

249 greater per cent improvement in Y-BOCS than DBS.

250 Overall, ABL utility was greater than DBS, with ABL showing a greater per cent improvement in

251 ive, have lower total misclassification than DBSs.

252 standard (i.e., venous whole blood) and that DBS is a suitable tool for assessing MeHg exposure in hu

253 Our results demonstrate that DBS implantation surgery may affect hemisphere volume at

254 These findings demonstrate that DBS-based genotypic drug resistance testing for HIV-2 is

255 Our results provide evidence that DBS of the ventral part of the anterior limb of the inte

256 This study supports the hypothesis that DBS provides long-term pain relief for the majority of C

257 sonance imaging (fMRI) studies indicate that DBS stimulation targets dependent brain network effects,

258 We observed that DBS implantation, but not the duration of stimulation, i

259 havioral marker of impulsivity and show that DBS affects impulsivity by amplifying automated respondi

260 gression revealed good agreement between the DBS ELISA method and reference assay data, with baseline

261 s determination of exact blood volume in the DBS punch and the quantitation of target analytes.

262 ted the concentrations of metabolites in the DBS samples depending on their abundance in the red bloo

263 BS handling is thus reduced to inserting the DBS punch into the CE vial only.

264 Alternatively, conductivity of the DBS eluate can be used for the blood volume determinatio

265 the blood volume originally sampled onto the DBS card.

266 f these 313 patients, 196 (63%) received the DBS implant and 191 (61%) were randomly assigned.

267 The stability results revealed that the DBS sampling strategy could improve compound stability.

268 d screening criteria were implanted with the DBS device bilaterally in the subthalamic nucleus.

269 ap of the region of influence of therapeutic DBS identified an optimal anatomical target site that ca

270 This DBS cohort completed the task under three conditions: on

271 PA) to demonstrate that stimulation of three DBS targets (STN, subthalamic nucleus; GPi, globus palli

272 hanges in mood and behaviour attributable to DBS, based upon an analysis of connectivity and its rela

273 lly variable subcortical zones correspond to DBS sites with less consistent treatment effects, highli

274 an 'at-risk' patients be identified prior to DBS; do neuropsychiatric symptoms relate to the distribu

275 e of adverse events in patients imaged under DBS vendor guidelines for MRI demonstrates the general s

276 of published cohorts of patients undergoing DBS for CCH, identified by a systematic review of MEDLIN

277 st and movement in people with PD undergoing DBS.

278 and movement in 37 people with PD undergoing DBS.

279 cohorts of patients (N = 50) that underwent DBS to the anterior limb of the internal capsule (ALIC),

280 the determination of blood volume in unknown DBS samples by punching out the entire DBS or by subpunc

281 and amino acids (target analytes) in unknown DBS samples.

282 o inborn metabolic disorders) in the unknown DBS was compared with a standard analytical procedure us

283 relevant measures will be analyzed in urine, DBS, or blood products from the older adult women.

284 vALIC DBS for TRD showed continued efficacy 2 years after surg

285 Here, we show that VCVS DBS' effect is explained in part by enhancement of PFC-d

286 s vs capillary) and matrices (whole blood vs DBS).

287 c terminals of SNpc neurons in PD brains vs. DBS-treated brains, DBS treatment seemed to have inhibit

288 Weekly DBS TFV-DP was measured by validated liquid chromatograp

289 The ability of a weekly DBS sampling and CRP test regime to detect flare outside

290 ubset of n = 30 RA patients submitted weekly DBS samples over the study period.

291 ndant (> 80%) in intergenic regions, whereas DBSs for H3K4me3 were distributed in all genomic regions

292 vidence to make a clear statement on whether DBS for OCD is established therapy.

293 sociated with lower action-reward bias while DBS was associated with higher action-reward bias.

294 However, clinical experience with DBS for OCD remains limited.

295 sonian nonhuman primates each implanted with DBS leads targeting the STN and GPi.

296 The main risks in patients with DBS devices undergoing MRI are heating at the electrode

297 ork for performing safe MRI in patients with DBS devices.

298 the general safety of MRI for patients with DBS devices.

299 d 12% for H3K27me3) of genes associated with DBSs matched with the levels of gene expression inferred

300 s; (iii) fourteen (14) genes associated with DBSs showed co-localization for both the marks; (iv) onl